课题基金 / 基金详情

Pediatric Transplant Infections and Outcomes

Pediatric Transplant Infections and Outcomes
儿科移植感染和结果
批准号:
7140407
负责人:
Vikas R. Dharnidharka
金额:
$14.21万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-08-01 至 2007-07-31

项目摘要

项目成果

Vikas R. Dharnidharka的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although transplant acute rejection rates have declined dramatically, in the most recent years, there have been almost no incremental gains in either short-term or longer-term graft survival (GS) rates (USRDS 2003 report). The applicants, in prior studies, have documented the rise in frequency in post-transplant infections (PTI; both bacterial and viral etiology) and post transplant lymphoproliferative disease (PTLD) in the uniquely susceptible pediatric population. There is a severe paucity of data regarding PTI trends and their impact on GS in children. In this proposal, the applicants will obtain data files from extremely large transplant databases (including USRDS and UNOS) on multiple transplantation variables, post transplant course, data on hospitalization, institutional billing claims for Medicare payment and patient death. These data will be analyzed to test the hypotheses that: 1) pediatric kidney transplant recipients are at greater risk for death due to PTI in months 6-36 as compared to adults; 2) hospitalization due to PTI, especially viral, is increasing in frequency in pediatric kidney transplant recipients in more recent cohorts; 3) this increase in hospitalization due to viral infections increases the risk of worse death-censored GS; 4) children who have received prior immunosuppression have a higher adjusted relative risk for post kidney transplant PTI and thus a reduced death-censored GS; 5) PTI involving the renal allograft itself (such as transplant pyelonephritis) represent an independent risk factor for reduced death-censored GS; 6) the relative risk of developing PTLD is higher in pediatric kidney transplant recipients who received induction therapy with daclizumab or basiliximab. These studies will set the stage for a) randomized prospective clinical trials on strategies to reduce PTI and result in improved GS; b) mechanistic studies that investigate how graft-directed immunity is affected by primary viral infections in pediatric kidney transplant recipients; c) development of a specific ICD-9 code for BK virus infection that will allow studies of its long-term effects.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Post-transplant lymphoproliferative disease: association with induction therapy?
移植后淋巴增殖性疾病:与诱导治疗相关吗?
DOI: 10.2165/00003495-200666040-00003
发表时间: 2006
期刊: Drugs
影响因子: 11.5
作者: [Dharnidharka,VikasR]
通讯作者: Dharnidharka,VikasR
Assessing the value of ureteral stent placement in pediatric kidney transplant recipients.
评估儿童肾移植受者输尿管支架置入的价值。
DOI: 10.1097/tp.0b013e318169bf11
发表时间: 2008
期刊: Transplantation
影响因子: 6.2
作者: [Dharnidharka,VikasR, Araya,CarlosE, Wadsworth,ChristopherS, McKinney,MichaelC, Howard,RichardJ]
通讯作者: Howard,RichardJ
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
  • 批准号:
    10755205
  • 项目类别:
  • 资助金额:
    $98.72万
  • 财政年份:
    2023
  • 负责人:
    Vikas R. Dharnidharka
  • 依托单位:
Pediatric Kidney Single Cell Atlas Project
  • 批准号:
    10530267
  • 项目类别:
  • 资助金额:
    $87.16万
  • 财政年份:
    2022
  • 负责人:
    Vikas R. Dharnidharka
  • 依托单位:
Pediatric Kidney Single Cell Atlas Project
  • 批准号:
    10707947
  • 项目类别:
  • 资助金额:
    $79.62万
  • 财政年份:
    2022
  • 负责人:
    Vikas R. Dharnidharka
  • 依托单位:
Metagenomic shotgun microbial sequencing in post-transplant lymphoproliferative disorders (PTLD-MSMS)
  • 批准号:
    10630142
  • 项目类别:
  • 资助金额:
    $55.54万
  • 财政年份:
    2019
  • 负责人:
    Vikas R. Dharnidharka
  • 依托单位:
海外基金